Vitamin K Supplementation in Patients on Hemodialysis

• Status: Completed
• Trial end date: 2017-12-18
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether vitamin K supplementation will improve anticoagulation control in patients on hemodialysis taking warfarin for atrial fibrillation. Patients who participate will receive vitamin K1 three times a week on dialysis days for a period of four months. INR levels collected during this period will be compared to the four month period prior to receiving the vitamin K1 to determine if vitamin K improves the standard deviation of INRs and time in therapeutic range.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Treatments: Vitamin K; Vitamin K 1; Vitamins; Warfarin

Criteria

Inclusion Criteria:

• greater than 18 years of age

• Receiving in-house hemodialysis for at least 6 months

• Previously diagnosed with atrial fibrillation

• On warfarin for at least 6 months with a target INR of 2-3

Exclusion Criteria:

• are unable to provide informed consent

• have a mechanical heart valve

• are receiving supplements containing vitamin K

• have a known hypersensitivity to vitamin K